Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23536865 | 0.90 | CRBN (0.47) | CRBNDDB1BRD4PARP1TNK2 | |
| SCHEMBL30159746 | 0.90 | CRBN (0.47) | CRBNDDB1BRD4PARP1TNK2 | |
| SCHEMBL23572687 | 0.88 | CRBN (0.49) | CRBNDDB1USP30BRD4 | |
| SCHEMBL30159844 | 0.88 | CRBN (0.49) | CRBNDDB1USP30BRD4 | |
| SCHEMBL31682899 | 0.88 | CRBN (0.49) | CRBNDDB1USP30BRD4 | |
| SCHEMBL23536816 | 0.83 | NR1H2 (0.39) | USP30 | |
| SCHEMBL23536803 | 0.83 | USP30 (0.35) | USP30 | |
| SCHEMBL29213893 | 0.81 | NR1H2 (0.38) | — | |
| SCHEMBL23593833 | 0.81 | CRBN (0.48) | CRBNDDB1USP30BRD4PARP1 | |
| SCHEMBL23594073 | 0.81 | CRBN (0.48) | CRBNDDB1USP30BRD4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-118059104-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-115175901-B | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4077309-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115175901-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021127443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | CRBN 151/4885DDB1 2540/4885USP30 2187/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CRBN 257/4885DDB1 1355/4885USP30 396/4885 |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CRBN 257/4885DDB1 1355/4885USP30 396/4885 |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CRBN 257/4885DDB1 1355/4885USP30 396/4885 |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CRBN 257/4885DDB1 1355/4885USP30 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.